Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.

Acute myeloid leukemia Chronic myelomonocytic leukemia EORTC item library Fatigue Modular measurement approach Myelodysplastic syndromes Patient-reported outcomes Physical functioning

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
20 Jul 2021
Historique:
received: 13 11 2020
accepted: 29 06 2021
entrez: 20 7 2021
pubmed: 21 7 2021
medline: 21 7 2021
Statut: epublish

Résumé

Physical functioning and fatigue are key patient concerns in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The objective of this research was to generate supportive quantitative evidence for modular physical functioning and fatigue measures based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and a customized selection of 10 supplemental items from the EORTC Item Library. The 40 items were completed online cross-sectionally by 51 patients (higher risk [HR] MDS: 53%; CMML: 26%; AML: 10%). Psychometric analyses based on Rasch measurement theory (RMT) were conducted on the QLQ-C30 physical functioning and fatigue domains as well as measures combining QLQ-C30 and supplemental items. A measure of anemia-related symptoms composed of QLQ-C30 and supplemental items covering fatigue, dyspnea, and dizziness was also investigated. The QLQ-C30 physical functioning and fatigue domains showed good targeting to the sample and adequate reliability, with few conceptual gaps identified. Combining the QLQ-C30 and supplemental physical functioning and fatigue items improved the conceptual coverage and the reliability of the measures. The patient-reported anemia-related symptom measure showed good measurement performance, underpinned by a clinically meaningful characterization of severity of these symptoms over a spectrum, starting with fatigue, then dyspnea, and finally dizziness (most severe). The modular measurement approach of combining EORTC QLQ-C30 and Item Library offers a promising pragmatic solution to the measurement of physical functioning and fatigue, as well as anemia-related symptoms in clinical trials conducted in HR MDS, CMML, and AML.

Identifiants

pubmed: 34283303
doi: 10.1186/s41687-021-00334-w
pii: 10.1186/s41687-021-00334-w
pmc: PMC8292469
doi:

Types de publication

Journal Article

Langues

eng

Pagination

60

Subventions

Organisme : Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
ID : Not applicable

Informations de copyright

© 2021. The Author(s).

Références

Clin Trials. 2018 Dec;15(6):616-623
pubmed: 30230365
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Orphanet J Rare Dis. 2017 Nov 2;12(1):171
pubmed: 29096663
Hematology Am Soc Hematol Educ Program. 2015;2015:496-500
pubmed: 26637764
Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):571-85
pubmed: 21958102
Haematologica. 2016 Jun;101(6):781-8
pubmed: 26944474
Clin Cancer Res. 2016 Nov 15;22(22):5618
pubmed: 28151715
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S57-63
pubmed: 27521326
J Patient Rep Outcomes. 2019 Jun 19;3(1):35
pubmed: 31218454
Health Qual Life Outcomes. 2016 May 06;14:72
pubmed: 27150974
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177
pubmed: 19216837
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
Blood. 2017 Aug 17;130(7):859-866
pubmed: 28694324
Recent Results Cancer Res. 1993;127:201-10
pubmed: 8502817
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
Clin Cancer Res. 2016 Apr 1;22(7):1553-8
pubmed: 26758559
Qual Life Res. 2020 Mar;29(3):815-823
pubmed: 31782016

Auteurs

Antoine Regnault (A)

Modus Outcomes, 4 Place Amédée Bonnet, 69002, Lyon, France. antoine.regnault@modusoutcomes.com.

Farrah Pompilus (F)

Modus Outcomes, Cambridge, MA, USA.

Anna Ciesluk (A)

Modus Outcomes, Cambridge, MA, USA.

Flora Mazerolle (F)

Modus Outcomes, 4 Place Amédée Bonnet, 69002, Lyon, France.

Rafael Bejar (R)

Moores Cancer Center, UC San Diego - MDS Center of Excellence, San Diego, CA, USA.

Robert J Fram (RJ)

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Douglas V Faller (DV)

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Patrick Marquis (P)

Modus Outcomes, Cambridge, MA, USA.

Jill A Bell (JA)

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Classifications MeSH